Omeros Achieves Profitability as Strategic Moves Slash Debt
Omeros Corporation has become profitable, reporting an $86.5 million net profit in Q4 2025, largely due to a $240 million asset sale to Novo Nordisk. The company also significantly reduced its debt by 47% to $88 million and successfully launched its new drug YARTEMLEA. Future revenues are anticipated from additional milestones with Novo Nordisk and an upcoming EMA regulatory decision for YARTEMLEA.
Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)
Omeros (NASDAQ:OMER) experienced unusually high options volume, with investors acquiring 7,487 call options, a 54% increase from typical volume. This activity follows a strong Q4 earnings report where the company posted a GAAP net income of $86.5M and an EPS of $3.14, significantly beating expectations and causing the stock to rise by 15.3%. Despite mixed analyst ratings, the company has a consensus price target of $40.33, and institutional investors hold a substantial portion of its stock.
Transcript : Omeros Corporation, Q4 2025 Earnings Call, Mar 31, 2026
This article is a transcript of Omeros Corporation's Q4 2025 Earnings Call, held on March 31, 2026. The earnings call was published on April 1, 2026, at 3:35 am EDT. The full content is reserved for subscribers.
Omeros: Q4 Earnings Snapshot
Omeros Corporation (OMER) reported a net income of $86.5 million, or 98 cents per share, in its fourth quarter. After adjustments, earnings were $3.14 per share. For the entire year, the company posted a net loss of $3.4 million, or 5 cents per share.
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism
Omeros Corporation's shares rose 5% after hours following the company's optimistic outlook regarding its deal with Novo Nordisk and the performance of its existing drugs. The company reported a net income of $86.5 million for the fourth quarter, significantly up from a loss in the previous year, partly due to a $237.6 million gain from the zaltenibart transaction with Novo Nordisk. Additionally, Omeros's Yartemlea drug, recently approved by the FDA, has commenced commercial distribution in the U.S. and awaits European approval.
Earnings call transcript: Omeros Corporation Q4 2025 sees remarkable earnings beat
Omeros Corporation (OMER) reported a significant earnings beat for Q4 2025, with an adjusted EPS of $3.14, far exceeding the forecast of -$0.52, and a revenue of $86.5 million. This financial turnaround was driven by the commercial launch of YARTEMLEA and a strategic $240 million upfront payment from Novo Nordisk for the zaltenibart asset. The company's stock responded positively, rising 2.45% in aftermarket trading, and management anticipates the YARTEMLEA program to be self-sustaining in 2026 and the company to achieve positive cash flow in 2027.
Omeros Corporation Reports Q4 and Full-Year 2025 Results
Omeros Corporation, a Seattle-based biopharmaceutical company, reported its financial results for the fourth quarter and full-year 2025, detailing revenue, expenses, and net income, alongside progress on its drug candidates. This report is crucial for investors and industry analysts to understand the company's performance, drug development pipeline, and commercial operations within the capital-intensive biotech industry. The company's ongoing efforts to advance its pipeline and maintain commercial operations are closely watched by industry observers.
Omeros: Q4 Earnings Snapshot
Omeros Corporation (OMER) reported a net income of $86.5 million for its fourth quarter, translating to 98 cents per share, or $3.14 per share when adjusted for one-time events. Despite the strong quarterly performance, the company recorded an annual loss of $3.4 million, or 5 cents per share. This financial snapshot was generated using data from Zacks Investment Research.
After $240M Novo deal, Omeros launches first approved TA-TMA drug
Omeros Corporation reported a Q4 2025 profit of $86.5 million, significantly up from a loss in Q4 2024, primarily due to a $240 million upfront payment from Novo Nordisk for exclusive global rights to zaltenibart. The company also announced the FDA approval and commercial launch of YARTEMLEA® (narsoplimab-wuug), the first and only approved therapy for TA-TMA. These achievements, along with progress in other pipeline programs like OncotoX-AML and T-CAT, position Omeros for potential positive cash flow by 2027.
Vanguard entities disaggregate OMER holdings (OMER) after internal realignment
The Vanguard Group has filed an amended Schedule 13G/A for Omeros Corp (OMER), reporting 0% beneficial ownership due to an internal realignment. This realignment disaggregates certain subsidiaries and business divisions, which will now report their beneficial ownership separately in accordance with SEC Release No. 34-39538. The filing clarifies that this is an administrative reclassification, not an economic trade, with Vanguard no longer deemed to have beneficial ownership over securities held by these separated entities.
Omeros Corp Stock: Biotech Innovator Focused on Complement Inhibitors Ahead of Q4 2025 Earnings
Omeros Corp (OMER) is a commercial-stage biotech company specializing in complement-mediated diseases, preparing to release its Q4 and full-year 2025 financial results on March 31, 2026. The company's lead product, YARTEMLEA, is FDA-approved for TA-TMA, and investors are keenly watching for sales updates, pipeline progress, and strategic developments. Omeros differentiates itself through its focused approach on MASP-2 inhibitors, aiming for reduced side effects compared to broader complement inhibitors.
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Omeros Corporation will release its financial results for the fourth quarter and full-year ended December 31, 2025, on Tuesday, March 31, 2026, after market close. Following the release, Omeros management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and recent developments. The company is a commercial-stage biotechnology firm focusing on protein and small-molecule therapeutics for various indications, including complement-mediated diseases and cancers.
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Omeros Corporation announced it will release its financial results for the fourth quarter and full-year 2025 on Tuesday, March 31, 2026, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and recent developments. Instructions for accessing the webcast and replay are provided, noting a transition to a new earnings call platform.
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Omeros Corporation (NASDAQ: OMER) announced it would release its fourth quarter and full-year 2025 financial results on Tuesday, March 31, 2026, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results, recent developments, and company highlights. The announcement also details Omeros' innovative biotechnology focus, including its FDA-approved drug YARTEMLEA® and its pipeline of therapeutics.
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Omeros Corporation (NASDAQ: OMER) announced it will release its financial results for the fourth quarter and full-year ended December 31, 2025, on Tuesday, March 31, 2026, after market close. Management will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss developments and financial results. The company highlighted its innovative biopharmaceutical pipeline, including its FDA-approved drug OMIDRIA® and other clinical-stage programs.
Omeros (OMER) Projected to Post Earnings on Monday
Omeros (NASDAQ:OMER) is expected to release its Q4 2025 earnings before market open on Monday, March 30, with analysts projecting a loss of ($0.55) per share and revenue of approximately $40.15 million. The stock currently holds a "Moderate Buy" rating with an average target price of $40.33, though analyst opinions vary. Insider selling has been noted, with institutional investors holding nearly half of the company's shares.
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Omeros Corporation will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will discuss the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Omeros' lead drug, YARTEMLEA, is FDA-approved for TA-TMA, and other pipeline assets include OMS1029 and OMS527.
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Omeros Corporation will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, in Madrid, Spain. The session will focus on "Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy." This announcement highlights Omeros's continued investment in innovative biopharmaceutical solutions, particularly their existing FDA-approved drug, OMERUUS, for stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Omeros Corporation will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, to discuss advances in TA-TMA treatment, focusing on a novel targeted therapy. The session will feature prominent experts from leading medical institutions. Omeros, a commercial-stage biotechnology company, is known for its FDA-approved drug YARTEMLEA® (narsoplimab-wuug) for TA-TMA, with a marketing authorization application currently under review in Europe.
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Omeros Corporation announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, in Madrid, Spain. The session will focus on advances in TA-TMA treatment and the role of novel targeted therapy, featuring experts in the field. Omeros is a biotechnology company with an FDA-approved drug, YARTEMLEA, for TA-TMA, and a pipeline of other therapeutics.
OMER SEC Filings - Omeros 10-K, 10-Q, 8-K Forms
This page provides access to Omeros Corporation's (NASDAQ: OMER) official SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. Stock Titan enhances these documents with AI-generated summaries to help investors quickly interpret key information regarding Omeros's biopharmaceutical activities, financial structure, and regulatory milestones. Recent filings highlight routine insider trading activity related to director stock option grants.
Omeros (NASDAQ:OMER) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
Omeros Corporation (NASDAQ:OMER) saw its stock price cross above its 200-day moving average, which currently stands at $9.15, with shares trading as high as $11.71. Analyst ratings for Omeros are mixed, but the consensus is a "Moderate Buy" with a target price of $40.33. Insider activity includes CAO David J. Borges selling 30,000 shares, while institutional investors hold nearly half of the company's stock.
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call
Omeros Corp has sold its immune-system drug, narsoplimab, specifically its ophthalmic and pediatric rare disease assets, to Novo Nordisk for a total consideration that could reach $2.1 billion. This deal includes an upfront payment of $95 million and potential milestones, with the transaction allowing Omeros to focus on its pivotal PNH and IgA Nephropathy clinical programs for narsoplimab, which faces an upcoming FDA decision.
Omeros rises after pricing ~$22M stock offering
Omeros (OMER) stock saw a rise after pricing a public offering of 8.8 million shares at $2.50 each, aiming to raise approximately $22 million. The offering includes pre-funded warrants and will use the proceeds for general corporate purposes, including working capital.
Omeros: Yartemlea Can Own The Label And Still Split The Market (NASDAQ:OMER)
Omeros (OMER) is maintained as a Hold due to the limited revenue potential of its drug YARTEMLEA and the company's valuation being largely tied to pipeline assets. YARTEMLEA faces market constraints from a small, fragmented target market, operational complexities, and anticipated payer pushback on its pricing. The updated model projects a peak market share of 40% and a net price of approximately $250,000, resulting in a roughly $300 million Net Present Value for YARTEMLEA, although uptake and pricing remain uncertain.
Omeros (NASDAQ: OMER) CEO exercises 400,000 options with tax share withholding
Omeros Corporation's CEO, Gregory A. Demopulos, exercised 400,000 stock options on February 18, 2026. The company withheld 357,678 shares to cover the exercise price and tax liability, with these shares remaining in the company's treasury. This transaction was not an open-market sale, and following the exercise, Demopulos directly owned 1,469,308 shares, in addition to indirect holdings.
Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Omeros Corporation (NASDAQ:OMER) has received a consensus "Moderate Buy" rating from five brokerages, with an average one-year price target of $40.33. While some analysts, like HC Wainwright, have significantly increased their price targets and maintained "buy" ratings, others, including Wall Street Zen and Weiss Ratings, have issued or reaffirmed "sell" ratings, indicating mixed views. Insider David J. Borges recently sold 30,000 shares, and institutional investors collectively hold nearly half of the stock.
Omeros announces completion of nonhuman primates OncotoX-AML study
Omeros (OMER) has completed an initial study in nonhuman primates for its OncotoX-AML cancer therapeutic platform, which targets acute myeloid leukemia. The study showed that a single course of OncotoX-AML treatment led to a significant, selective, and reversible reduction of myeloid progenitor cells by up to 99% while being well-tolerated with no significant safety signals. This development is promising as current AML treatments are often limited by substantial side effects.
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
Omeros Corporation announced the successful completion of an initial nonhuman primate study for its OncotoX-AML™ cancer therapeutic platform, targeting acute myeloid leukemia (AML). The study showed that a single treatment course led to a significant, selective, and reversible reduction in myeloid progenitor cells by up to 99 percent, with no major safety signals. Omeros plans to initiate IND-enabling studies to advance OncotoX-AML™ to clinical trials, aiming for a first-in-human trial in late 2027.
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
Omeros Corporation announced successful completion of a nonhuman primate study for its OncotoX-AML therapeutic, targeting acute myeloid leukemia (AML). The study showed that a single course of OncotoX-AML treatment effectively and selectively reduced myeloid progenitor cells by up to 99% without significant side effects, outperforming current standard-of-care in preclinical models. Omeros plans to initiate IND-enabling studies soon, with a first-in-human trial targeted for late 2027.
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside
Omeros (OMER) stock surged in premarket trading following FDA approval for its drug, narsoplimab, the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This approval is seen as a significant long-term growth driver, with analysts predicting substantial revenue and potential for Omeros to become a major pharmaceutical company, despite concerns about trial sizes.
Omeros Achieves Commercial Milestone with First Approved Drug Launch
Omeros Corporation has commenced the commercial launch of its FDA-approved drug, YARTEMLEA®, in the U.S. for transplant-associated thrombotic microangiopathy (TA-TMA). This milestone, along with a significant licensing deal with Novo Nordisk for $2.1 billion, positions Omeros as a commercial-stage entity with bolstered financial resources. The company anticipates an EMA decision for YARTEMLEA® mid-year and plans to release its Q4/full-year 2025 financial results between March 3 and April 2.
Omeros Achieves Commercial Milestone with First Approved Drug Launch
Omeros Corporation has launched its first FDA-approved therapy, YARTEMLEA®, in the U.S. for transplant-associated thrombotic microangiopathy (TA-TMA), marking its transition into a commercial-stage company. Concurrently, Omeros secured a significant licensing deal with Novo Nordisk for its investigational drug, Zaltenibart, including an upfront payment of $240 million, which is expected to cover debt and operations for over a year. The company aims for positive cash flow by 2027 and anticipates a European marketing authorization decision for YARTEMLEA® around mid-year.
Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions
Omeros Corporation (NASDAQ: OMER) saw its market cap fall by US$60 million last week, impacting both individual investors, who collectively own 50% of the company, and institutional investors holding 47%. The article highlights the significant influence individual investors have due to their substantial ownership and notes insider selling activity. Despite this, institutional holdings suggest some professional credibility, and analysts are covering the stock.
Omeros Corporation (NASDAQ:OMER) Sees Large Growth in Short Interest
Omeros Corporation (NASDAQ:OMER) experienced a significant 24% increase in short interest in January, reaching over 16.4 million shares, which represents about 26.6% of its shares sold short. This surge comes as institutional investors like UBS and Vanguard reportedly increased their holdings in the company. Despite insider selling by the CAO, analysts maintain a "Moderate Buy" consensus rating for Omeros, with a target price of $40.33.
Omeros begins commercial distribution of TA-TMA treatment Yartemlea By Investing.com
Omeros Corporation has commenced commercial distribution of its FDA-approved drug, Yartemlea (narsoplimab-wuug), for the treatment of stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The company's stock has seen significant returns despite recent volatility, with analysts projecting considerable upside. While Omeros appears overvalued by some metrics, analysts anticipate profitability this fiscal year, alongside recent positive financial news including a narrower-than-expected loss in Q3 2025 and a substantial deal with Novo Nordisk.
Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital
D. Boral Capital has reiterated a "Buy" rating for Omeros (NASDAQ:OMER) with a price target of $36.00, suggesting a potential upside of over 200%. The biopharmaceutical company currently holds a "Moderate Buy" consensus rating from analysts, with an average target price of $40.33. This report also highlights recent insider selling activity and institutional investor sentiment.
Omeros stock rises as first commercial YARTEMLEA shipments begin
Omeros Corporation (NASDAQ:OMER) saw its stock rise after commencing commercial shipments of YARTEMLEA (narsoplimab-wuug), its FDA-approved therapy for stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This makes YARTEMLEA the first and only FDA-approved treatment for this potentially fatal condition, benefiting both adult and pediatric patients. A marketing authorization application is also under review by the European Medicines Agency.
Omeros Announces First Commercial Sales of YARTEMLEA®
Omeros Corporation has announced the first commercial sales of its drug YARTEMLEA® (narsoplimab-wuug), the first and only FDA-approved therapy for stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Initial shipments have been sent to distributors, and the drug is now being administered to both adult and pediatric TA-TMA patients in various transplant centers. A marketing authorization application for YARTEMLEA is also under review by the European Medicines Agency.
Omeros wins first commercial sales of Yartemlea (OMER:NASDAQ)
Omeros Corporation (OMER) shares rose after the company announced its first commercial shipments of Yartemlea. This recently FDA-approved therapy is designed to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication that can arise from stem cell transplantation. The news highlights a significant commercial milestone for the Seattle-based biotech firm.
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages
Omeros Corporation (NASDAQ:OMER) has received a consensus "Moderate Buy" rating from five brokerages, with an average 12-month price target of $40.33. Recent analyst upgrades include HC Wainwright raising its target to $40 and WBB Securities issuing a $45 strong-buy rating. The company's stock trades around $11.53, and analysts forecast a -3.09 EPS for the current fiscal year, despite a recent quarterly earnings beat.
Omeros wins FDA nod for transplant therapy
Omeros has received FDA approval for its transplant therapy. This regulatory milestone marks a significant achievement for the company in the pharmaceutical industry. The approval is expected to impact the treatment landscape for transplant patients.
Omeros wins FDA nod for transplant therapy
This article reports that Omeros has received approval from the FDA for its transplant therapy. This significant regulatory milestone is expected to impact the company's market position and patient treatment options.
Omeros Shares Face Headwinds Amid Mixed Signals
Omeros Corporation's stock is experiencing significant volatility due to insider selling, a mixed market reaction to regulatory approval, and conflicting analyst opinions. While the FDA approved YARTEMLEA, investors are focusing on its commercial launch trajectory after Omeros divested rights to another therapy. Insider transactions, such as the Chief Accounting Officer selling shares, have further impacted market sentiment.
Omeros (NASDAQ:OMER) Shares Down 5.8% Following Insider Selling
Omeros (NASDAQ:OMER) shares dropped 5.8% after CAO David J. Borges sold 30,000 shares for $369,300. The biopharmaceutical company has a consensus "Moderate Buy" rating from analysts with an average target price of $40.33, significantly higher than its current share price of approximately $12.32. Institutional investors and hedge funds own 48.79% of the company's stock.
Omeros VP Borges sells $750k in shares
Omeros' VP of Finance & CAO, David J. Borges, sold 60,000 shares of common stock for over $750,000. He also exercised options to acquire 30,000 shares. This news follows the company's positive third-quarter 2025 financial results, FDA approval for Yartemlea, and a significant transaction with Novo Nordisk for its MASP-3 inhibitor.
Omeros (OMER) Price Target Increased by 29.70% to 44.54
The one-year price target for Omeros (OMER) has been increased by 29.70% to $44.54 per share, up from $34.34. This new average target is based on analyst estimates ranging from $36.36 to $57.75 and represents a significant increase of 240.65% from its latest closing price of $13.08. Institutional ownership in Omeros remains strong, with a slight decrease in the number of funds holding positions but an overall increase in total shares owned by institutions.
Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares
Omeros Corporation's (NASDAQ:OMER) Chief Administrative Officer, David Borges, sold 30,000 shares of the company's stock on January 13th for a total of $369,300. This insider transaction comes as Omeros shares traded up on Wednesday, with a market capitalization of $927.37 million. Analysts have mixed but generally positive ratings for OMER, with a consensus target price of $40.33.
Omeros VP Borges sells $750k in shares By Investing.com
Omeros's VP of Finance & CAO, David J. Borges, sold 60,000 shares of common stock for approximately $750,915 and also exercised options to acquire 30,000 shares. This insider trading news follows Omeros' positive third-quarter 2025 financial results, including lower-than-expected losses, FDA approval for its drug Yartemlea, and a significant transaction with Novo Nordisk for its MASP-3 inhibitor, zaltenibart, valued up to $2.1 billion.
Omeros VP Borges sells $750k in shares
Omeros's VP of Finance & CAO, David J. Borges, sold 60,000 shares of common stock for approximately $750,915 and exercised options to acquire 30,000 shares for $91,800. This insider trading news follows Omeros's positive third-quarter 2025 results, including a narrower-than-expected loss and FDA approval for its drug Yartemlea, as well as a significant licensing deal with Novo Nordisk for zaltenibart.
